Trial
NCT01420523
Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
ANRS, Emerging Infectious Diseases
Collaborators
Merck Sharp & Dohme LLC; ViiV Healthcare
Condition
Human Immunodeficiency Virus
Intervention
Raltegravir-Maraviroc
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-02